Canaccord Genuity Reiterates a 'Buy' on Tranzyme (TZYM); Double-edged Sword: Cubist Enters POI
Tweet
Share
E-mailGet Alerts TZYM Hot Sheet
Price: $0.48 --0%
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Tranzyme (NASDAQ: TZYM) price target of $7.00.
Canaccord Genuity analyst, Ritu Baral, said, "Reiterate rating and price target on lead drug ulimorelin’s (uli’s) potential for Phase 3 and commercial success in postoperative ileus (POI). POI is a post-surgical gut disorder that leads to longer hospital stays and higher healthcare costs. We believe the two uli Phase 3 POI trials will yield positive data in H1/12, an NDA submission in early 2013 and a 2014 launch."
"Entereg marketing by Cubist (Nasdaq: CBST) may be a double--edged sword for uli. Cubist’s marketing muscle should help raise profile of POI and the pharmacoeconomic advantages of decreasing hospital stays. We think this may prime the market for uli’s launch. On the flip side, Entereg is likely to gain formulary adoptions and become a stronger competitor to uli."
For more ratings news on Tranzyme click here and for the rating history of Tranzyme click here.
Shares of Tranzyme closed at $3.00 yesterday.
Canaccord Genuity analyst, Ritu Baral, said, "Reiterate rating and price target on lead drug ulimorelin’s (uli’s) potential for Phase 3 and commercial success in postoperative ileus (POI). POI is a post-surgical gut disorder that leads to longer hospital stays and higher healthcare costs. We believe the two uli Phase 3 POI trials will yield positive data in H1/12, an NDA submission in early 2013 and a 2014 launch."
"Entereg marketing by Cubist (Nasdaq: CBST) may be a double--edged sword for uli. Cubist’s marketing muscle should help raise profile of POI and the pharmacoeconomic advantages of decreasing hospital stays. We think this may prime the market for uli’s launch. On the flip side, Entereg is likely to gain formulary adoptions and become a stronger competitor to uli."
For more ratings news on Tranzyme click here and for the rating history of Tranzyme click here.
Shares of Tranzyme closed at $3.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- New Street Research Upgrades Micron Technology (MU) to Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
